| Browse by: | Sort by: |
Immunotherapy: How Does It Work?
Bryan Haugen, MD
University of Colorado School of Medicine, Aurora, CO
Available
Immunotherapy: Does it Work?
Camilo Jimenez, MD
University of Texas MD Anderson Cancer Center, Houston, TX
Available
Immunotherapy: Does it Hurt?
Carla Moran, MB, PhD
Beacon Hospital, Dublin, Ireland
Available
Quieting the Estrogen Receptor for Therapeutic Benefit in ER+ Breast Cancer
Ciara Metcalfe, PhD
Genentech, Inc, South San Francisco, CA
Available
Molecular Subtypes of Prostate Cancer
Christopher Barbieri, MD, PhD
Weill Cornell Medicine, New York, NY
Available
WNT/Beta-Catenin Signaling in Prostate Cancer
Susan Logan, PhD
New York University Langone Medical Center, New York, NY
Available
Exploiting How Membrane Receptors Signal Inside Cells: Example of c-MET
Stéphanie Kermorgant, PhD
Barts Cancer Institute, Queen Mary University London, London, United Kingdom
Available
Abstract Presentation: Steroid Receptor Co-Activators Regulate Metabolic Kinases to Drive Therapy Resistant ER+ Breast Cancer
Thu Truong, PhD
University of Minnesota, Minneapolis, MN
Available
Targeting the Sodium Iodide Symporter to Increase RAI Uptake
Christopher McCabe, PhD
University of Birmingham, Birmingham, United Kingdom
Available
Developing Novel Combination Therapies for Medullary Thyroid Cancer
Rozita Bagheri-Yarmand, PhD
University of Texas MD Anderson Cancer Center, Houston, TX
Available
Genetic Determinants Underlying Radioiodine Refractory Thyroid Cancer
Sissy Jhiang, PhD
The Ohio State University Medical Center, Columbus, OH
Available
Abstract Presentation: Aggressive Thyroid Cancer is Associated With Suppressor Circulating Immunophenotype
Anupam Kotwal, MD
Univ. of Nebraska Medical Center, Omaha, NE
Available
Chair
Patricia Dahia, MD, PhD
University of Texas Health Science Center at San Antonio, San Antonio, TX
Chair
Mimi Hu, MD
University of Texas MD Anderson Cancer Center, Houston, TX
Welcome and Introductions
Molecular and Clinical Facets of Parathyroid Cancer
William Simonds, MD
National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
Live Moderated Q&A
Proteomics and Medullary Thyroid Cancer
Wayne Miles, PhD
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Live Moderated Q&A
Molecular Targeted Therapy for the Treatment of Thyroid Neoplasia and Cancer
Marcia Brose, MD, PhD
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Live Moderated Q&A and Session Closing
Available
Chair
Rebecca Riggins, PhD
Georgetown University, Washington, DC
Pro-Tumorigenic Role of Neutrophil Elastase in Lymphangioleiomyomatosis (LAM)
Erin Gibbons, MS
UNIVERSITY OF ROCHESTER, Rochester, NY
Audience Q&A
Thyroid Hormone and Estrogen Promote Endocrine Resistance, Proliferation, Dedifferentiation, and Cancer Stem Cells in Steroid Receptor-Positive Breast Cancers
Reema Wahdan-Alaswad, PhD, MS
University of Colorado Anschutz Medical Campus, Aurora, CO
Audience Q&A
ERa-Dependent Lethal Hyperactivation of the Anticipatory Unfolded Protein Response Induces Complete Regression Without Recurrence of Advanced Breast Cancer
Darjan Duraki, BS Biochemistry
University of Illinois at Urbana-Champaign, Urbana, IL
Audience Q&A
Identification of Genes and Pathways Differentially Expressed in Progestin Responsive Endometrial Cancer and Hyperplasia
Jay Gertz, PhD
University of Utah, SALT LAKE CITY, UT
Audience Q&A
Available
Chair
Elaine Alarid, PhD
University of Wisconsin - Madison, Madison, WI
Welcome and Introductions
Androgen Receptor Enhancers in Control of Prostate Cancer Development and Progression
Wilbert Zwart, PhD
Netherlands Cancer Institute, Amsterdam, Netherlands
Live Moderated Q&A
Tumor Cell Total mRNA Expression Shapes the Molecular and Clinical Phenotype of Cancer
Wenyi Wang, PhD
The University of Texas MD Anderson, Houston, TX
Live Moderated Q&A
Available
Aggressive Pituitary Tumors and Carcinomas: Two Sides of the Same Coin?
Jacqueline Trouillas, MD, PhD
University of Lyon, Lyon, France
Slides + audio
Available
Treatment of Aggressive Pituitary Tumors and Carcinomas
Ann I McCormack, MD, PhD
St. Vincent's Hospital, Sydney, Australia
Slides + audio
Coming soon
Molecular Underpinnings of the Aggressive Pituitary Tumor
Gerald Raverot, MD, PhD
Hospices Civils de Lyon, Lyon Cedex 03, France
Slides + audio
Available
Thyroid Cancer Genetics and Implications for Therapy
Nikita Pozdeyev, MD, PhD
University of Colorado, Aurora, CO
Slides + audio
Available
A Glimmer of Hope: Novel Combination Therapy for the Treatment of Anaplastic Thyroid Cancer
Maria E Cabanillas, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Slides + audio
Available
Super-Enhancer Targeting in Advanced Thyroid Cancers
Matthew D Ringel, MD
The Ohio State University, Columbus, OH
Slides + audio
Available
Questions and Answers
Mabel M Ryder, MD
Mayo Clinic, Rochester, MN, United States
Nikita Pozdeyev, MD, PhD
University of Colorado, Aurora, CO
Maria E Cabanillas, MD
The University of Texas MD Anderson Cancer Center, Houston, TX
Matthew D Ringel, MD
The Ohio State University, Columbus, OH
Unknown permission
for presentation
for presentation
Application of New Adrenal Cancer Models to Screen Therapeutics
Katja Kiseljak-Vassiliades, DO
University of Colorado, Denver, Aurora, CO
Slides + audio
Available
New In Vitro Models for Studying Human Adreno-Cortical Cancer (ACC)
Leo J Hofland, PHD
Erasmus Medical Center, Rotterdam, Netherlands
Slides + audio
Available
Mouse Models of Adrenal Tumors
Pierre Val, PhD
National Center for Scientific Research, Clermont-Ferrand, France
Slides + audio
Available
